Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis
Purpose: Oral mucositis (OM) is a debilitating side effect of cisplatin and intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer. The phase 3 ROMAN trial showed avasopasem manganese (AVA) significantly decreased individual endpoints of incidence and duration of severe o...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Advances in Radiation Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452109424002379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846151074902179840 |
|---|---|
| author | Carryn Anderson, MD Samuel Salvaggio, PhD Mickaël De Backer, PhD Jean-Christophe Chiem, PhD Gary Walker, MD, MPH, MS Deborah Saunders, DMD, BSc Christopher M. Lee, MD Neal Dunlap, MD Eugene Kennedy, MD Robert Beardsley, PhD Benton Schoen, BA Marc Buyse, ScD |
| author_facet | Carryn Anderson, MD Samuel Salvaggio, PhD Mickaël De Backer, PhD Jean-Christophe Chiem, PhD Gary Walker, MD, MPH, MS Deborah Saunders, DMD, BSc Christopher M. Lee, MD Neal Dunlap, MD Eugene Kennedy, MD Robert Beardsley, PhD Benton Schoen, BA Marc Buyse, ScD |
| author_sort | Carryn Anderson, MD |
| collection | DOAJ |
| description | Purpose: Oral mucositis (OM) is a debilitating side effect of cisplatin and intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer. The phase 3 ROMAN trial showed avasopasem manganese (AVA) significantly decreased individual endpoints of incidence and duration of severe oral mucositis (SOM, World Health Organization [WHO] grade 3-4), with nominal decrease in severity (WHO grade 4) and significant increase in the delay in onset of SOM. We sought to determine the Net Treatment Benefit (NTB) of AVA versus placebo (PBO) using the generalized pairwise comparisons (GPC) method. Methods and Materials: GPC is a statistical method that permits simultaneous analysis of several prioritized outcomes, comparing all possible pairs of a patient in the active (ie, AVA) group and a patient from the control (ie, PBO) group. NTB is the net benefit across all the outcomes for AVA compared to PBO. Key clinically relevant outcomes from ROMAN were prioritized: (1) WHO grade 4 OM incidence; (2) SOM incidence; (3) days of SOM; (4) days to SOM onset, with 7 days difference defined as the clinical relevance threshold for SOM days and SOM onset. Results: GPC analysis of 407 patients (AVA = 241, placebo = 166) stratified by cisplatin schedule and treatment setting resulted in 13,969 pairwise comparisons. AVA showed statistically significant net benefit on all 4 key outcomes with a 53.9% probability that AVA would benefit patients versus a 35.0% probability that PBO would; the difference between these probabilities was a NTB of 18.9% (P = .0012), translating to an AVA number needed to treat of 5.3 patients. All outcomes contributed to NTB, reflecting improvements in SOM incidence, onset and duration, and in grade 4 OM incidence seen in the original ROMAN analysis. Conclusions: This GPC analysis shows compelling evidence from the ROMAN trial of AVA's clinical benefit across key parameters of SOM burden. |
| format | Article |
| id | doaj-art-e98caa25f385439f830d743c53eed531 |
| institution | Kabale University |
| issn | 2452-1094 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Advances in Radiation Oncology |
| spelling | doaj-art-e98caa25f385439f830d743c53eed5312024-11-28T04:34:47ZengElsevierAdvances in Radiation Oncology2452-10942025-01-01101101674Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary AnalysisCarryn Anderson, MD0Samuel Salvaggio, PhD1Mickaël De Backer, PhD2Jean-Christophe Chiem, PhD3Gary Walker, MD, MPH, MS4Deborah Saunders, DMD, BSc5Christopher M. Lee, MD6Neal Dunlap, MD7Eugene Kennedy, MD8Robert Beardsley, PhD9Benton Schoen, BA10Marc Buyse, ScD11Department of Radiation Oncology University of Iowa Hospitals & Clinics, Iowa City, Iowa; Corresponding author: Carryn M. Anderson, MDInternational Drug Development Institute (IDDI), Louvain-la-Neuve, BelgiumInternational Drug Development Institute (IDDI), Louvain-la-Neuve, BelgiumInternational Drug Development Institute (IDDI), Louvain-la-Neuve, BelgiumBanner MD Anderson Cancer Center, Gilbert, ArizonaNortheast Cancer Centre of Health Sciences North, Health Sciences North, Northern Ontario School of Medicine, Sudbury, CanadaCancer Care Northwest, Spokane, WashingtonUniversity of Louisville/James Graham Brown Cancer Center, Louisville, KentuckyGalera Therapeutics, Inc, Malvern, PennsylvaniaGalera Therapeutics, Inc, Malvern, PennsylvaniaGalera Therapeutics, Inc, Malvern, PennsylvaniaInternational Drug Development Institute (IDDI), Louvain-la-Neuve, BelgiumPurpose: Oral mucositis (OM) is a debilitating side effect of cisplatin and intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer. The phase 3 ROMAN trial showed avasopasem manganese (AVA) significantly decreased individual endpoints of incidence and duration of severe oral mucositis (SOM, World Health Organization [WHO] grade 3-4), with nominal decrease in severity (WHO grade 4) and significant increase in the delay in onset of SOM. We sought to determine the Net Treatment Benefit (NTB) of AVA versus placebo (PBO) using the generalized pairwise comparisons (GPC) method. Methods and Materials: GPC is a statistical method that permits simultaneous analysis of several prioritized outcomes, comparing all possible pairs of a patient in the active (ie, AVA) group and a patient from the control (ie, PBO) group. NTB is the net benefit across all the outcomes for AVA compared to PBO. Key clinically relevant outcomes from ROMAN were prioritized: (1) WHO grade 4 OM incidence; (2) SOM incidence; (3) days of SOM; (4) days to SOM onset, with 7 days difference defined as the clinical relevance threshold for SOM days and SOM onset. Results: GPC analysis of 407 patients (AVA = 241, placebo = 166) stratified by cisplatin schedule and treatment setting resulted in 13,969 pairwise comparisons. AVA showed statistically significant net benefit on all 4 key outcomes with a 53.9% probability that AVA would benefit patients versus a 35.0% probability that PBO would; the difference between these probabilities was a NTB of 18.9% (P = .0012), translating to an AVA number needed to treat of 5.3 patients. All outcomes contributed to NTB, reflecting improvements in SOM incidence, onset and duration, and in grade 4 OM incidence seen in the original ROMAN analysis. Conclusions: This GPC analysis shows compelling evidence from the ROMAN trial of AVA's clinical benefit across key parameters of SOM burden.http://www.sciencedirect.com/science/article/pii/S2452109424002379 |
| spellingShingle | Carryn Anderson, MD Samuel Salvaggio, PhD Mickaël De Backer, PhD Jean-Christophe Chiem, PhD Gary Walker, MD, MPH, MS Deborah Saunders, DMD, BSc Christopher M. Lee, MD Neal Dunlap, MD Eugene Kennedy, MD Robert Beardsley, PhD Benton Schoen, BA Marc Buyse, ScD Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis Advances in Radiation Oncology |
| title | Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis |
| title_full | Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis |
| title_fullStr | Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis |
| title_full_unstemmed | Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis |
| title_short | Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis |
| title_sort | benefit of avasopasem manganese on severe oral mucositis in head and neck cancer in the roman trial unplanned secondary analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2452109424002379 |
| work_keys_str_mv | AT carrynandersonmd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT samuelsalvaggiophd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT mickaeldebackerphd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT jeanchristophechiemphd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT garywalkermdmphms benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT deborahsaundersdmdbsc benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT christophermleemd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT nealdunlapmd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT eugenekennedymd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT robertbeardsleyphd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT bentonschoenba benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis AT marcbuysescd benefitofavasopasemmanganeseonsevereoralmucositisinheadandneckcancerintheromantrialunplannedsecondaryanalysis |